<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631445</url>
  </required_header>
  <id_info>
    <org_study_id>TD2-PDAC-KETO-001</org_study_id>
    <nct_id>NCT04631445</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer</brief_title>
  <official_title>Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Drug Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Genomics Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Drug Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of the ketogenic diet in patients with metastatic&#xD;
      pancreatic cancer while receiving chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, phase II trial designed to evaluate the progression free survival in patients&#xD;
      with metastatic pancreatic cancer on triplet therapy (nab-paclitaxel + gemcitabine +&#xD;
      cisplatin) while on ketogenic diet or non-ketogenic diet. This study also aims to compare the&#xD;
      changes in serum metabolites and quality of life between the two arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Ketogenic diet with standard of care chemotherapy versus non-ketogenic diet with standard of care chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival per RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from randomization to first documentation of objective tumor progression or to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the number of responses by RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
    <description>To compare the number of complete responses/partial responses as defined by CT scan using the Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) and CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9) down to normal limits (from at least &gt; 2X ULN).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the disease control rate using the Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1).</measure>
    <time_frame>36 months</time_frame>
    <description>(Partial Response + Complete Response + Stable Disease for at least 9 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Biomarkers</measure>
    <time_frame>36 months</time_frame>
    <description>Change in CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Biomarkers returning to normal</measure>
    <time_frame>36 months</time_frame>
    <description>Rates of normalization of CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>36 months</time_frame>
    <description>To compare the average weight (kg), using BMI calculation (BMI = weight (kg) / height (m2))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare insulin levels</measure>
    <time_frame>36 months</time_frame>
    <description>To compare average insulin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the average HbgA1c level</measure>
    <time_frame>36 months</time_frame>
    <description>To compare the average HbgA1c levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare changes in serum metabolites</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare quality of life between arms via the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire QLC-C30 (EORTC QLQ-C30) assessment.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Ketogenic (KD) + Triplet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ketogenic + Triplet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-ketogenic diet plus nab-paclitaxel 125 mg/m2, cisplatin 25 mg/m2, and gemcitabine 1000 mg/m2 all administered intravenously (IV) on Days 1 and 8 every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ketogenic Diet</intervention_name>
    <description>Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to &lt; 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).</description>
    <arm_group_label>Ketogenic (KD) + Triplet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years of age; male or female.&#xD;
&#xD;
          2. Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma,&#xD;
             not previously treated for their metastatic disease.&#xD;
&#xD;
          3. Capable of providing informed consent and complying with trial procedures.&#xD;
&#xD;
          4. Karnofsky Performance Status (KPS) of ≥ 70%.&#xD;
&#xD;
          5. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          6. Measurable tumor lesions according to RECIST 1.1 criteria.&#xD;
&#xD;
          7. &lt;Grade 2 pre-existing peripheral neuropathy per NCI CTCAE, Version 5.0.&#xD;
&#xD;
          8. Patient has acceptable coagulation status as indicated by an INR ≤1.5 times&#xD;
             institutional upper limit of normal (ULN). Patients on anticoagulation can be included&#xD;
             at the discretion of the investigator.&#xD;
&#xD;
          9. Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count ≥1,500/mm3&#xD;
&#xD;
               -  Platelet concentration ≥100,000/mm3 with no platelet transfusions within 7 days&#xD;
                  prior to laboratory sample&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0g/dL (PRBCs may be given to meet this criteria)&#xD;
&#xD;
               -  Hematocrit level ≥ 27%&#xD;
&#xD;
               -  Total bilirubin within 1.25 x ULN&#xD;
&#xD;
               -  AST (SGOT), ALT (SGPT) and Alkaline phosphatase ≤ 2.5 times upper limit of normal&#xD;
                  (if liver metastases are present, then ≤ 5 x ULN is allowed)&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 mg/dL.&#xD;
&#xD;
         10. Patient must have a Smartphone or computer in order to work with Virta&#xD;
&#xD;
         11. Females of child-bearing potential (defined as a sexually mature woman who (1) has not&#xD;
             undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy&#xD;
             [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal&#xD;
             for at least 24 consecutive months [i.e., has had menses at any time during the&#xD;
             preceding 24 consecutive months]) must:&#xD;
&#xD;
               1. Either commit to true abstinence* from heterosexual contact (which must be&#xD;
                  reviewed on a monthly basis), or agree to use, and be able to comply with,&#xD;
                  effective contraception without interruption, 28 days prior to starting IP&#xD;
                  therapy (including dose interruptions), and while on study medication or for a&#xD;
                  longer period if required by local regulations following the last dose of IP; and&#xD;
&#xD;
               2. Have a negative serum pregnancy test (β -hCG) result at screening and agree to&#xD;
                  ongoing pregnancy testing during the course of the study, and after the end of&#xD;
                  study therapy. This applies even if the subject practices true abstinence* from&#xD;
                  heterosexual contact.&#xD;
&#xD;
         12. Male subjects must practice true abstinence* or agree to use a condom during sexual&#xD;
             contact with a pregnant female or a female of childbearing potential while&#xD;
             participating in the study, during dose interruptions and for 6 months following&#xD;
             discontinuation from study treatment, even if he has undergone a successful vasectomy.&#xD;
&#xD;
               -  True abstinence is acceptable when this is in line with the preferred and usual&#xD;
                  lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation,&#xD;
                  symptothermal, post-ovulation methods) and withdrawal are not acceptable methods&#xD;
                  of contraception].&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients must have received no previous radiotherapy, surgery, chemotherapy or&#xD;
             investigational therapy for the treatment of their metastatic pancreatic disease.&#xD;
&#xD;
          2. Evidence of central nervous system (CNS) metastasis (negative imaging study, if&#xD;
             clinically indicated, within 4 weeks of Screening Visit).&#xD;
&#xD;
          3. History of other malignancies (except cured basal cell carcinoma, superficial bladder&#xD;
             cancer or carcinoma in situ of the cervix) unless documented free of cancer for ≥ 2&#xD;
             years.&#xD;
&#xD;
          4. Uncontrolled intercurrent illness, including but not limited to New York Heart&#xD;
             Association Class III or IV, myocardial infarction within the past 6 months, or&#xD;
             unstable arrhythmia.&#xD;
&#xD;
          5. Known infection with HIV, hepatitis B, or hepatitis C.&#xD;
&#xD;
          6. Active, uncontrolled bacterial, viral, or fungal infections, requiring systematic&#xD;
             therapy.&#xD;
&#xD;
          7. Major surgery within 4 weeks prior to study entry. (Port-a-cath may be inserted during&#xD;
             this time period).&#xD;
&#xD;
          8. Any condition in the opinion of the principal investigator that might interfere with&#xD;
             the patient's participation in the study or in the evaluation of the study results.&#xD;
&#xD;
          9. Any condition in the opinion of the principal investigator that is unstable and could&#xD;
             jeopardize the patient's participation in the study.&#xD;
&#xD;
         10. Unwillingness or inability to comply with procedures required in this protocol,&#xD;
             including unwillingness to follow a ketogenic diet.&#xD;
&#xD;
         11. Severe malnutrition or body mass index (BMI) &lt; 18.&#xD;
&#xD;
         12. Albumin &lt; 3.5 g/dL.&#xD;
&#xD;
         13. History of Type 1 diabetes.&#xD;
&#xD;
         14. History of diabetic ketoacidosis (DKA).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brittany Porter, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Translational Drug Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brittany Porter, MPH</last_name>
    <phone>602-358-8370</phone>
    <email>bporter@td2inc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katie Gazarik</last_name>
    <phone>602.358.8336</phone>
    <email>kgazarik@td2inc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jockquin Ross</last_name>
      <email>jocross@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Gayle Jameson, NP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walker Brock, RN</last_name>
      <email>walker.brock@hoag.org</email>
    </contact>
    <contact_backup>
      <last_name>Rabia Rehman</last_name>
      <email>rabia.rehman@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Diana Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuvance Health</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elaina Vicari</last_name>
      <email>Elaina.Vicari@nuvancehealth.org</email>
    </contact>
    <investigator>
      <last_name>Richard Frank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Ginder</last_name>
      <email>nancy.ginder@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Angela Alistar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Lurati, RN</last_name>
      <phone>210-593-5290</phone>
      <email>tiffany.lurati@startsa.com</email>
    </contact>
    <investigator>
      <last_name>Drew Rasco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Pancreatic Ductal Adenocarcinoma</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Ketogenic Diet</keyword>
  <keyword>Keto Diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

